Skip to main navigation

Keyword Search

Subscribe to receive breaking news alerts about uniQure.

  • Subscribe
Date Title  
Mar 13, 2023
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 02, 2023
uniQure to Participate in Multiple Upcoming Industry Conferences in March
Feb 27, 2023
uniQure Announces 2022 Financial Results and Highlights Recent Company Progress
Feb 23, 2023
uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)
Feb 21, 2023
uniQure announces the European Commission approval of the first gene therapy for adults with hemophilia B
Jan 31, 2023
uniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1